Copy to clipboard 
Orthofix Medical reported 1Q26 orthopedic sales of $196.7 million, up 1.6% compared to the first quarter of 2025.
Results were better than they appear at first glance. Excluding sales from the discontinued M6 line, the company’s spine business grew nearly 6%. The top 30 distributors grew their sales 27% in the first quarter compared to the prior year’s first quarter.
In trauma, Orthofix sunset about 30 product lines in 2025 as it transitions to focus on complex limb reconstruction. Additionally, timing of its OSCAR capital sales offset some gains in the U.S.
One area in need of work for Orthofix is biologics.
“While Spine is benefiting from better alignment, we are applying the same discipline to Biologics,” said company CEO Massimo Calafiore. “Performance improved sequentially during the quarter as we implemented targeted actions to strengthen execution, expand account penetration and increase utilization across the portfolio. We are refining our go-forward strategy, building clinical evidence and supporting advocacy.”
Orthofix reaffirmed its previous stated guidance of sales between $850 million and $860 million, reflecting approximately 5.5% pro forma growth.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $74.4 | $74.5 | ($0.1) | (0.1%) |
| Trauma | $32.9 | $29.8 | $3.0 | 10.2% |
| Orthobiologics | $30.1 | $32.6 | ($2.5) | (7.7%) |
| Enabling Technology | $1.5 | $1.6 | ($0.1) | (5.7%) |
| Other (Bone Growth Therapies) | $57.8 | $55.1 | $2.7 | 4.9% |
| Total | $196.7 | $193.6 | $3.1 | 1.6% |
Orthopedic Sales by Geography
| Region | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $161.3 | $161.7 | ($0.4) | (0.2%) |
| OUS | $35.4 | $32.0 | $3.4 | 10.7% |
| EMEA | $14.6 | $12.9 | $1.7 | 12.8% |
| ROW | $20.8 | $19.0 | $1.8 | 9.2% |
| Total | $196.7 | $193.6 | $3.1 | 1.6% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $196.7 | |
| Cost of Sales | $57.2 | 29.1% |
| Selling, General, Admin | $134.9 | 68.6% |
| R & D | $15.3 | 7.8% |
| Other | $10.2 | 5.2% |
| Net Earnings | ($20.9) | (10.6%) |
Orthofix Medical reported 1Q26 orthopedic sales of $196.7 million, up 1.6% compared to the first quarter of 2025.
Results were better than they appear at first glance. Excluding sales from the discontinued M6 line, the company's spine business grew nearly 6%. The top 30 distributors grew their sales 27% in the first quarter compared to the...
Orthofix Medical reported 1Q26 orthopedic sales of $196.7 million, up 1.6% compared to the first quarter of 2025.
Results were better than they appear at first glance. Excluding sales from the discontinued M6 line, the company’s spine business grew nearly 6%. The top 30 distributors grew their sales 27% in the first quarter compared to the prior year’s first quarter.
In trauma, Orthofix sunset about 30 product lines in 2025 as it transitions to focus on complex limb reconstruction. Additionally, timing of its OSCAR capital sales offset some gains in the U.S.
One area in need of work for Orthofix is biologics.
“While Spine is benefiting from better alignment, we are applying the same discipline to Biologics,” said company CEO Massimo Calafiore. “Performance improved sequentially during the quarter as we implemented targeted actions to strengthen execution, expand account penetration and increase utilization across the portfolio. We are refining our go-forward strategy, building clinical evidence and supporting advocacy.”
Orthofix reaffirmed its previous stated guidance of sales between $850 million and $860 million, reflecting approximately 5.5% pro forma growth.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $74.4 | $74.5 | ($0.1) | (0.1%) |
| Trauma | $32.9 | $29.8 | $3.0 | 10.2% |
| Orthobiologics | $30.1 | $32.6 | ($2.5) | (7.7%) |
| Enabling Technology | $1.5 | $1.6 | ($0.1) | (5.7%) |
| Other (Bone Growth Therapies) | $57.8 | $55.1 | $2.7 | 4.9% |
| Total | $196.7 | $193.6 | $3.1 | 1.6% |
Orthopedic Sales by Geography
| Region | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $161.3 | $161.7 | ($0.4) | (0.2%) |
| OUS | $35.4 | $32.0 | $3.4 | 10.7% |
| EMEA | $14.6 | $12.9 | $1.7 | 12.8% |
| ROW | $20.8 | $19.0 | $1.8 | 9.2% |
| Total | $196.7 | $193.6 | $3.1 | 1.6% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $196.7 | |
| Cost of Sales | $57.2 | 29.1% |
| Selling, General, Admin | $134.9 | 68.6% |
| R & D | $15.3 | 7.8% |
| Other | $10.2 | 5.2% |
| Net Earnings | ($20.9) | (10.6%) |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
